These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 34145536)

  • 1. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
    Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
    Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias?
    Mascolo A; Sportiello L; Rafaniello C; Donniacuo M; Ruggiero D; Scisciola L; Barbieri M; Rossi F; Paolisso G; Capuano A
    Biomed Pharmacother; 2023 Aug; 164():114912. PubMed ID: 37210896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database.
    Ruggiero R; Fraenza F; Scavone C; di Mauro G; Piscitelli R; Mascolo A; Ferrajolo C; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Pharmacol; 2020; 11():830. PubMed ID: 32581796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports.
    Khurana A; Dubey H; Arora MK
    Curr Drug Saf; 2024; 19(3):382-394. PubMed ID: 38310553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
    Guo Q; Gao J; Guo H; Xie J; Cheng J
    Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Ientile V; Santarpia M; Ferlazzo G; Fontana A; Carrega P; Matarangolo E; Barnaba S; Spina E; Trifirò G
    Br J Clin Pharmacol; 2021 Feb; 87(2):527-541. PubMed ID: 32495965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study.
    Haeuser L; Marchese M; Cone EB; Noldus J; Bayliss G; Kilbridge KL; Trinh QD
    Nephrol Dial Transplant; 2022 Jun; 37(7):1310-1316. PubMed ID: 34028534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.
    Ma R; Wang Q; Meng D; Li K; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):38. PubMed ID: 33413213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
    Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
    Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
    Fan Q; Chen H; Hu Y; Zhao B
    Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases.
    Rabbani SA; Khurana A; El-Tanani M; Arora MK; Sharma S; Sridhar SB; Dubey H
    Expert Opin Drug Saf; 2024 Oct; ():. PubMed ID: 39392233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors.
    Cutroneo P; Ingrasciotta Y; Isgrò V; Rullo EV; Berretta M; Fiorica F; Trifirò G; Guarneri C
    Dermatol Ther; 2021 Mar; 34(2):e14830. PubMed ID: 33527643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database.
    Nicoletti MM; Crisci E; Cosenza V; Riccardi C; Campitiello MR; Ruggiero D; Berrino PM; Docimo G; Scavone C
    Drugs Real World Outcomes; 2024 Mar; 11(1):33-41. PubMed ID: 37907712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
    Wang H; Yang H; Zhou X; Zhang X
    Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database.
    Liu G; Zhang S; Mo Z; Huang T; Yu Q; Lu X; He P
    Front Pharmacol; 2024; 15():1407894. PubMed ID: 38953101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.